Xiaojun Liu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Xiaojun Liu has a total of 91 co-authors. Here are the top co-authors by number of shared publications:
Fude Fang
Department of Biochemistry & Molecular Biology, State Key Laboratory of Common Mechanism Research for Major Diseases, Institute of Basic Medical Sciences & School of Basic Medicine, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100005, China
10 shared publicationsXianghong Xie
Department of Biochemistry & Molecular Biology, State Key Laboratory of Common Mechanism Research for Major Diseases, Institute of Basic Medical Sciences Chinese Academy of Medical Sciences & School of Basic Medicine Peking Union Medical College, Beijing, China
7 shared publicationsYiting Wang
Department of Biochemistry and Molecular Biology, State Key Laboratory of Common Mechanism Research for Major Diseases, Institute of Basic Medical Sciences & School of Basic Medicine, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China
7 shared publicationsChunmei Li
Department of Biochemistry & Molecular Biology, State Key Laboratory of Common Mechanism Research for Major Diseases, Institute of Basic Medical Sciences Chinese Academy of Medical Sciences & School of Basic Medicine Peking Union Medical College, Beijing, China
6 shared publicationsEnhui Chen
Department of Pathophysiology, State Key Laboratory of Common Mechanism Research for Major Diseases, Institute of Basic Medical Sciences Chinese Academy of Medical Sciences & School of Basic Medicine Peking Union Medical College, Beijing, China
6 shared publicationsJiahui Yang
Department of Microbiology and Immunology, Shanxi Medical University, Taiyuan, China
6 shared publications
Latest Publications
- 12 October 2026
- Published by Springer Nature in Acta Diabetologica
- p. 1-12
Targeting ceramides in metabolic syndrome: recent advances and therapeutic opportunities
- 12 October 2026
- Published by Springer Nature in Acta Diabetologica
- p. 1-12
Targeting ceramides in metabolic syndrome: recent advances and therapeutic opportunities
- Open Access
Celastrol alleviates SGLT2 inhibitor-induced diabetic hyperketonemia by inhibiting hepatic ketogenesis
SGLT2 inhibitor (SGLT2i)-induced diabetic hyperketonemia is a life-threatening acute complication of diabetes. While Celastrol has been reported to exert beneficial effects on obesity; its potential role in ketogenesis remains unclear. In this study, Celastrol administration significantly attenuates the fasting-induced elevation of blood β-hydroxybutyrate. Moreover, a 7-day course of Celastrol (1 mg/kg/day) leads to reductions in body weight and fat mass. Mechanistically, Celastrol specifically downregulates HMGCS2 expression and suppressess hepatic ketogenesis through inhibiting PPARα expression in the short term (≤ 2 days). However, after prolonged treatment for 7 days, Celastrol modulates both PPARαand serum free fatty acids (FFAs) levels. Furthermore, anti-ketogenic effect of Celastrol is abolished in Ppar α□ / □ mice. Importantly, Celastrol effectively ameliorates SGLT2i-induced hyperketonemia. In summary, Celastrol curbs hepatic ketone overproduction in a PPARα-dependent manner, indicating its protective potential against SGLT2i-induced hyperketonemia.
Open AccessCelastrol alleviates SGLT2 inhibitor-induced diabetic hyperketonemia by inhibiting hepatic ketogenesis
SGLT2 inhibitor (SGLT2i)-induced diabetic hyperketonemia is a life-threatening acute complication of diabetes. While Celastrol has been reported to exert beneficial effects on obesity; its potential role in ketogenesis remains unclear. In this study, Celastrol administration significantly attenuates the fasting-induced elevation of blood β-hydroxybutyrate. Moreover, a 7-day course of Celastrol (1 mg/kg/day) leads to reductions in body weight and fat mass. Mechanistically, Celastrol specifically downregulates HMGCS2 expression and suppressess hepatic ketogenesis through inhibiting PPARα expression in the short term (≤ 2 days). However, after prolonged treatment for 7 days, Celastrol modulates both PPARαand serum free fatty acids (FFAs) levels. Furthermore, anti-ketogenic effect of Celastrol is abolished in Ppar α□ / □ mice. Importantly, Celastrol effectively ameliorates SGLT2i-induced hyperketonemia. In summary, Celastrol curbs hepatic ketone overproduction in a PPARα-dependent manner, indicating its protective potential against SGLT2i-induced hyperketonemia.
- Open Access
- 25 July 2025
- Published by Elsevier in Journal of Biological Chemistry
- Vol. 301 (9) , 110500
The ribonucleoprotein hnRNP K promotes hepatic steatosis by suppressing the nuclear hormone receptor PPARα
- 25 July 2025
- Published by Elsevier in Journal of Biological Chemistry
- Vol. 301 (9) , 110500
Open AccessThe ribonucleoprotein hnRNP K promotes hepatic steatosis by suppressing the nuclear hormone receptor PPARα
- 11 April 2025
- Published by Wiley in The FASEB Journal
- Vol. 39 (7) , e70458
Identification of CDKN1A as a potential key risk factor in MASLD progression
Metabolic dysfunction‐associated steatotic liver disease (MASLD), previously referred to as non‐alcoholic fatty liver disease (NAFLD), is recognized as a highly heterogeneous condition. The elusive mechanisms driving its progression contribute to the lack of reliable diagnostic markers and effective treatments. In this study, we first identified 52 differentially expressed genes (DEGs) in MASLD stage by analyzing two public datasets, GSE126848 and GSE135251, using the DESeq2 and edgeR packages. Subsequently, these DEGs were subjected to protein–protein interaction (PPI) network analysis, revealing the top 10 hub genes. By intersecting the top 10 hub genes with another public dataset GSE260222, we observed that CDKN1A was the sole gene consistently upregulated in the livers of MASLD patients across all analyses. The elevated protein expression of CDKN1A was further validated in the livers of MASLD patients compared to control subjects. Consistently, compared to their respective control groups, both CDKN1A mRNA and protein levels were dramatically increased in the livers of MASLD animal models, including high‐fat diet (HFD) induced obese mice, leptin‐deficient obese ( ob/ob ) mice and leptin receptor‐deficient ( db/db ) mice, and in mouse primary hepatocytes treated with free fatty acids (FFA), respectively. Interestingly, we found that CDKN1A transcript levels were progressively and significantly increased with the severity of MASLD in four out of five datasets and positively correlated with both the NAFLD activity score (NAS) and fibrosis stage, two important clinicopathological features of MASLD. Collectively, our results illustrated that CDKN1A may serve as a promising biomarker and therapeutic target for MASLD; however, its role in the disease's pathology warrants further investigation.
- 11 April 2025
- Published by Wiley in The FASEB Journal
- Vol. 39 (7) , e70458
Identification of CDKN1A as a potential key risk factor in MASLD progression
Metabolic dysfunction‐associated steatotic liver disease (MASLD), previously referred to as non‐alcoholic fatty liver disease (NAFLD), is recognized as a highly heterogeneous condition. The elusive mechanisms driving its progression contribute to the lack of reliable diagnostic markers and effective treatments. In this study, we first identified 52 differentially expressed genes (DEGs) in MASLD stage by analyzing two public datasets, GSE126848 and GSE135251, using the DESeq2 and edgeR packages. Subsequently, these DEGs were subjected to protein–protein interaction (PPI) network analysis, revealing the top 10 hub genes. By intersecting the top 10 hub genes with another public dataset GSE260222, we observed that CDKN1A was the sole gene consistently upregulated in the livers of MASLD patients across all analyses. The elevated protein expression of CDKN1A was further validated in the livers of MASLD patients compared to control subjects. Consistently, compared to their respective control groups, both CDKN1A mRNA and protein levels were dramatically increased in the livers of MASLD animal models, including high‐fat diet (HFD) induced obese mice, leptin‐deficient obese ( ob/ob ) mice and leptin receptor‐deficient ( db/db ) mice, and in mouse primary hepatocytes treated with free fatty acids (FFA), respectively. Interestingly, we found that CDKN1A transcript levels were progressively and significantly increased with the severity of MASLD in four out of five datasets and positively correlated with both the NAFLD activity score (NAS) and fibrosis stage, two important clinicopathological features of MASLD. Collectively, our results illustrated that CDKN1A may serve as a promising biomarker and therapeutic target for MASLD; however, its role in the disease's pathology warrants further investigation.
- 30 October 2024
- Published by Elsevier in Biochemical and Biophysical Research Communications
- Vol. 737, 150919
Flll32, a curcumin analog, improves adipose tissue thermogenesis
- 30 October 2024
- Published by Elsevier in Biochemical and Biophysical Research Communications
- Vol. 737, 150919
Flll32, a curcumin analog, improves adipose tissue thermogenesis
- 24 October 2024
- Published by Elsevier in Life Sciences
- Vol. 358, 123172
Targeting histamine in metabolic syndrome: Insights and therapeutic potential
- 24 October 2024
- Published by Elsevier in Life Sciences
- Vol. 358, 123172
Targeting histamine in metabolic syndrome: Insights and therapeutic potential
- Open Access
- 22 October 2024
- Published by eLife Sciences Publications, Ltd in eLife
- Vol. 13
LncRNA Snhg3 aggravates hepatic steatosis via PPARγ signaling
LncRNAs are involved in modulating the individual risk and the severity of progression in metabolic dysfunction-associated fatty liver disease (MASLD), but their precise roles remain largely unknown. This study aimed to investigate the role of lncRNA Snhg3 in the development and progression of MASLD, along with the underlying mechanisms. The result showed that Snhg3 was significantly downregulated in the liver of high-fat diet-induced obesity (DIO) mice. Notably, palmitic acid promoted the expression of Snhg3 and overexpression of Snhg3 increased lipid accumulation in primary hepatocytes. Furthermore, hepatocyte-specific Snhg3 deficiency decreased body and liver weight, alleviated hepatic steatosis and promoted hepatic fatty acid metabolism in DIO mice, whereas overexpression induced the opposite effect. Mechanistically, Snhg3 promoted the expression, stability and nuclear localization of SND1 protein via interacting with SND1, thereby inducing K63-linked ubiquitination modification of SND1. Moreover, Snhg3 decreased the H3K27me3 level and induced SND1-mediated chromatin loose remodeling, thus reducing H3K27me3 enrichment at the Pparg promoter and enhancing PPARγ expression. The administration of PPARγ antagonist T0070907 improved Snhg3-aggravated hepatic steatosis. Our study revealed a new signaling pathway, Snhg3/SND1/H3K27me3/PPARγ, responsible for mice MASLD and indicates that lncRNA-mediated epigenetic modification has a crucial role in the pathology of MASLD.
- 22 October 2024
- Published by eLife Sciences Publications, Ltd in eLife
- Vol. 13
Open AccessLncRNA Snhg3 aggravates hepatic steatosis via PPARγ signaling
LncRNAs are involved in modulating the individual risk and the severity of progression in metabolic dysfunction-associated fatty liver disease (MASLD), but their precise roles remain largely unknown. This study aimed to investigate the role of lncRNA Snhg3 in the development and progression of MASLD, along with the underlying mechanisms. The result showed that Snhg3 was significantly downregulated in the liver of high-fat diet-induced obesity (DIO) mice. Notably, palmitic acid promoted the expression of Snhg3 and overexpression of Snhg3 increased lipid accumulation in primary hepatocytes. Furthermore, hepatocyte-specific Snhg3 deficiency decreased body and liver weight, alleviated hepatic steatosis and promoted hepatic fatty acid metabolism in DIO mice, whereas overexpression induced the opposite effect. Mechanistically, Snhg3 promoted the expression, stability and nuclear localization of SND1 protein via interacting with SND1, thereby inducing K63-linked ubiquitination modification of SND1. Moreover, Snhg3 decreased the H3K27me3 level and induced SND1-mediated chromatin loose remodeling, thus reducing H3K27me3 enrichment at the Pparg promoter and enhancing PPARγ expression. The administration of PPARγ antagonist T0070907 improved Snhg3-aggravated hepatic steatosis. Our study revealed a new signaling pathway, Snhg3/SND1/H3K27me3/PPARγ, responsible for mice MASLD and indicates that lncRNA-mediated epigenetic modification has a crucial role in the pathology of MASLD.
- Open Access
- 16 September 2024
- Published by eLife Sciences Publications, Ltd in eLife preprints
- Vol. 13
LncRNA Snhg3 Aggravates Hepatic Steatosis via PPARγ Signaling
LncRNAs are involved in modulating the individual risk and the severity of progression in metabolic dysfunction-associated fatty liver disease (MASLD), but their precise roles remain largely unknown. This study aimed to investigate the role of lncRNA Snhg3 in the development and progression of MASLD, along with the underlying mechanisms. In vitro and in vivo experiments revealed that Snhg3 is involved in lipid metabolism and steatosis. The result showed that Snhg3 was significantly downregulated in the liver of high-fat diet-induced obesity (DIO) mice. Notably, palmitic acid promoted the expression of Snhg3 and overexpression of Snhg3 increased lipid accumulation in primary hepatocytes. Furthermore, hepatocyte-specific Snhg3 deficiency decreased body and liver weight, alleviated hepatic steatosis and promoted hepatic fatty acid metabolism in DIO mice, whereas overexpression induced the opposite effect. Mechanistically, Snhg3 promoted the expression, stability and nuclear localization of SND1 protein via interacting with SND1, thereby inducing K63-linked ubiquitination modification of SND1. Moreover, Snhg3 decreased the H3K27me3 level and induced SND1-mediated chromatin loose remodeling, thus reducing H3K27me3 enrichment at the Pparγ promoter and enhancing Pparγ expression. The administration of PPARγ inhibitor T0070907 improved Snhg3-aggravated hepatic steatosis. Our study revealed a new signaling pathway, Snhg3/SND1/H3K27me3/PPARγ, responsible for MASLD and indicates that lncRNA-mediated epigenetic modification has a crucial role in the pathology of MASLD.
- 16 September 2024
- Published by eLife Sciences Publications, Ltd in eLife preprints
- Vol. 13
Open AccessLncRNA Snhg3 Aggravates Hepatic Steatosis via PPARγ Signaling
LncRNAs are involved in modulating the individual risk and the severity of progression in metabolic dysfunction-associated fatty liver disease (MASLD), but their precise roles remain largely unknown. This study aimed to investigate the role of lncRNA Snhg3 in the development and progression of MASLD, along with the underlying mechanisms. In vitro and in vivo experiments revealed that Snhg3 is involved in lipid metabolism and steatosis. The result showed that Snhg3 was significantly downregulated in the liver of high-fat diet-induced obesity (DIO) mice. Notably, palmitic acid promoted the expression of Snhg3 and overexpression of Snhg3 increased lipid accumulation in primary hepatocytes. Furthermore, hepatocyte-specific Snhg3 deficiency decreased body and liver weight, alleviated hepatic steatosis and promoted hepatic fatty acid metabolism in DIO mice, whereas overexpression induced the opposite effect. Mechanistically, Snhg3 promoted the expression, stability and nuclear localization of SND1 protein via interacting with SND1, thereby inducing K63-linked ubiquitination modification of SND1. Moreover, Snhg3 decreased the H3K27me3 level and induced SND1-mediated chromatin loose remodeling, thus reducing H3K27me3 enrichment at the Pparγ promoter and enhancing Pparγ expression. The administration of PPARγ inhibitor T0070907 improved Snhg3-aggravated hepatic steatosis. Our study revealed a new signaling pathway, Snhg3/SND1/H3K27me3/PPARγ, responsible for MASLD and indicates that lncRNA-mediated epigenetic modification has a crucial role in the pathology of MASLD.
- 12 August 2024
- Published by Wiley in The FASEB Journal
- Vol. 38 (15) , e23880
LncRNA ‐ Snhg3 regulates mouse hepatic glycogenesis under normal chow diet
Long noncoding RNAs (lncRNAs) are strongly associated with glucose homeostasis, but their roles remain largely unknown. In this study, the potential role of lncRNA‐ Snhg3 in glucose metabolism was evaluated both in vitro and in vivo. Here, we found a positive relationship between Snhg3 and hepatic glycogenesis. Glucose tolerance improved in hepatocyte‐specific Snhg3 knock‐in ( Snhg3 ‐HKI) mice, while it worsened in hepatocyte‐specific Snhg3 knockout ( Snhg3 ‐HKO) mice. Furthermore, hepatic glycogenesis had shown remarkable increase in Snhg3 ‐HKI mice and reduction in Snhg3 ‐HKO mice, respectively. Mechanistically, Snhg3 increased mRNA and protein expression levels of PPP1R3B through inducing chromatin remodeling and promoting the phosphorylation of protein kinase B. Collectively, these results suggested that lncRNA‐ Snhg3 plays a critical role in hepatic glycogenesis.
- 12 August 2024
- Published by Wiley in The FASEB Journal
- Vol. 38 (15) , e23880
LncRNA ‐ Snhg3 regulates mouse hepatic glycogenesis under normal chow diet
Long noncoding RNAs (lncRNAs) are strongly associated with glucose homeostasis, but their roles remain largely unknown. In this study, the potential role of lncRNA‐ Snhg3 in glucose metabolism was evaluated both in vitro and in vivo. Here, we found a positive relationship between Snhg3 and hepatic glycogenesis. Glucose tolerance improved in hepatocyte‐specific Snhg3 knock‐in ( Snhg3 ‐HKI) mice, while it worsened in hepatocyte‐specific Snhg3 knockout ( Snhg3 ‐HKO) mice. Furthermore, hepatic glycogenesis had shown remarkable increase in Snhg3 ‐HKI mice and reduction in Snhg3 ‐HKO mice, respectively. Mechanistically, Snhg3 increased mRNA and protein expression levels of PPP1R3B through inducing chromatin remodeling and promoting the phosphorylation of protein kinase B. Collectively, these results suggested that lncRNA‐ Snhg3 plays a critical role in hepatic glycogenesis.
- Open Access
LncRNA Snhg3 Aggravates Hepatic Steatosis via PPARγ Signaling
LncRNAs are involved in modulating the individual risk and the severity of progression in metabolic dysfunction-associated fatty liver disease (MASLD), but their precise roles remain largely unknown. This study aimed to investigate the role of lncRNA Snhg3 in the development and progression of MASLD, along with the underlying mechanisms. The result showed that Snhg3 was significantly downregulated in the liver of high-fat diet-induced obesity (DIO) mice. Notably, palmitic acid promoted the expression of Snhg3 and overexpression of Snhg3 increased lipid accumulation in primary hepatocytes. Furthermore, hepatocyte-specific Snhg3 deficiency decreased body and liver weight, alleviated hepatic steatosis and promoted hepatic fatty acid metabolism in DIO mice, whereas overexpression induced the opposite effect. Mechanistically, Snhg3 promoted the expression, stability and nuclear localization of SND1 protein via interacting with SND1, thereby inducing K63-linked ubiquitination modification of SND1. Moreover, Snhg3 decreased the H3K27me3 level and induced SND1-mediated chromatin loose remodeling, thus reducing H3K27me3 enrichment at the Ppar γ promoter and enhancing Ppar γ expression. The administration of PPARγ antagonist T0070907 improved Snhg3 -aggravated hepatic steatosis. Our study revealed a new signaling pathway, Snhg3 /SND1/H3K27me3/PPARγ, responsible for MASLD and indicates that lncRNA-mediated epigenetic modification has a crucial role in the pathology of MASLD.
Open AccessLncRNA Snhg3 Aggravates Hepatic Steatosis via PPARγ Signaling
LncRNAs are involved in modulating the individual risk and the severity of progression in metabolic dysfunction-associated fatty liver disease (MASLD), but their precise roles remain largely unknown. This study aimed to investigate the role of lncRNA Snhg3 in the development and progression of MASLD, along with the underlying mechanisms. The result showed that Snhg3 was significantly downregulated in the liver of high-fat diet-induced obesity (DIO) mice. Notably, palmitic acid promoted the expression of Snhg3 and overexpression of Snhg3 increased lipid accumulation in primary hepatocytes. Furthermore, hepatocyte-specific Snhg3 deficiency decreased body and liver weight, alleviated hepatic steatosis and promoted hepatic fatty acid metabolism in DIO mice, whereas overexpression induced the opposite effect. Mechanistically, Snhg3 promoted the expression, stability and nuclear localization of SND1 protein via interacting with SND1, thereby inducing K63-linked ubiquitination modification of SND1. Moreover, Snhg3 decreased the H3K27me3 level and induced SND1-mediated chromatin loose remodeling, thus reducing H3K27me3 enrichment at the Ppar γ promoter and enhancing Ppar γ expression. The administration of PPARγ antagonist T0070907 improved Snhg3 -aggravated hepatic steatosis. Our study revealed a new signaling pathway, Snhg3 /SND1/H3K27me3/PPARγ, responsible for MASLD and indicates that lncRNA-mediated epigenetic modification has a crucial role in the pathology of MASLD.